ライフサイエンスコーパス: tumor-specific antigen

1 rough improved immune surveillance against a tumor-specific antigen.

2 Id) protein, secreted by myeloma cells, is a tumor-specific antigen.

3 membrane protein could be transformed into a tumor-specific antigen.

4 containing a conventional plasmid carrying a tumor-specific antigen.

5 nes (BCR-ABL) oncogen product is a potential tumor-specific antigen.

6 ts (idiotype [Id]) that can be regarded as a tumor-specific antigen.

7 erminant (idiotype [Id]) that may serve as a tumor-specific antigen.

8 zes the human and murine equivalents of this tumor-specific antigen.

9 the melanoma antigen gene (MAGE-I) family of tumor-specific antigens.

10 8+ cytotoxic T cell responses against murine tumor-specific antigens.

11 nt on transplantable tumors, not against the tumor-specific antigens.

12 The MAGE proteins are best known as curious tumor-specific antigens.

13 on that does not depend on identification of tumor-specific antigens.

14 uction of immunity to weak antigens, such as tumor-specific antigens.

15 sequences represent potentially immunogenic tumor-specific antigens.

16 protein is a surprisingly broad, yet highly tumor-specific, antigen.

17 ow that host T cells properly primed against tumor-specific antigens after conventional treatment, wh

18 pressed by malignant B cells, idiotype, is a tumor-specific antigen and an attractive target for acti

19 B-cell malignancy (Id) can serve as a unique tumor-specific antigen and as a model for cancer vaccine

20 t has been hampered by the lack of universal tumor-specific antigens and a limited understanding of t

21 ncogenic proteins, such as E7, are promising tumor-specific antigens and are obligatory for tumor gro

22 Despite the existence of tumor-specific antigens and demonstrated presence of tum

23 show that MYCN-derived peptides can serve as tumor-specific antigens and suggest a rational approach

24 The combination of CRCL as a source of tumor-specific antigens and Th-1 lymphocytes as an adjuv

25 ulatory processes, which cause expression of tumor-specific antigens and tumor-associated antigens (T

26 CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients

27 Many tumor-specific antigens are mutant proteins that are pre

28 MJ23 T(regs) were not reactive to a tumor-specific antigen but instead recognized a prostate

29 that single-chain antibody fragments against tumor-specific antigens can be inserted at the N terminu

30 apy in which cytotoxic T cells (CTLs) target tumor-specific antigens complexed to MHC-I molecules has

31 mor antigen (Tag) represents a virus-encoded tumor-specific antigen expressed in many types of human

32 of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a therapeutic vaccine.

33 tumor cells produced hs2dAb directed against tumor-specific antigens further highlighting the potenti

34 Because tumor-specific antigens have been identified in multiple

35 However, few truly tumor-specific antigens have been identified, and health

36 Enhanced cytosolic bioavailability of tumor-specific antigens improves access to human leukocy

37 Leukemia cells may express tumor specific antigens in association with Class I and

38 ), also known as ETAA16, was identified as a tumor-specific antigen in the Ewing family of tumors.

39 Such sequences may thus comprise absolutely tumor-specific antigens in a peptide-based vaccine.

40 herapy using monoclonal antibodies against a tumor-specific antigen is now an established mode of the

41 In the B-cell lineage, CD160 is a tumor-specific antigen known to mediate cellular activat

42 that active immunization with genes encoding tumor-specific antigens may be an efficacious strategy f

43 een a hypothetical concern that mutations in tumor-specific antigens may lead to tumor escape.

44 In an effort to identify tumor-specific antigens recognized by CD4(+) T cells, an

45 of the quaternary structure of the secreted tumor-specific antigen reduces its immunogenicity.

46 mal tissues, and there is a paucity of truly tumor-specific antigens shared across tumor types.

47 unization of allogeneic BMT donors against a tumor-specific antigen significantly enhances GVT activi

48 es of the innate immune response against the tumor-specific antigen simian virus 40 (SV40) large tumo

49 against malignant cell types that express a tumor-specific antigen such as SV40 Tag.

50 strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic protei

51 In the future, the molecular definition of tumor-specific antigens that are recognized by activated

52 the utility of this approach for identifying tumor-specific antigens that are the targets of a CTL re

53 ients with cutaneous T-cell lymphoma express tumor-specific antigens that can serve as the targets of

54 we have studied two CD4(+) T cell-recognized tumor-specific antigens that were retained during evolut

55 in stimulating type 1 responses against our tumor-specific antigen, the male antigen, HY.

56 bacterium, is a potent vector for targeting tumor-specific antigens to the immune system.

57 ved Ig, the idiotype of which can serve as a tumor-specific antigen, to test the principle of transfe

58 alloantigens, although both alloantigens and tumor-specific antigens (TSAs) initiate GVT responses.

59 essed on the surface of B-cell lymphomas are tumor-specific antigens (TSAs), which can be targeted by

60 remains limited by the rarity of targetable tumor-specific antigens, tumor-mediated immune suppressi

61 The nanodrug binds the tumor-specific antigen uMUC-1, which is found in >90% of

62 Lymphomas express a tumor-specific antigen which can be targeted by cancer v

63 immunization of BMT donors against a defined tumor-specific antigen with a vaccine not containing rec